Biohaven Ltd
BHVN15.110USD
+1.750+13.10%
Cierre 07/17, 16:00（ET）Cotizaciones retrasadas 15 min
1.54BCap. mercado
PérdidaP/E TTM
Más Datos de Biohaven Ltd Compañía
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Información de la empresa
Símbolo de cotizaciónBHVN
Nombre de la empresaBiohaven Ltd
Fecha de salida a bolsaSep 23, 2022
Fundada en2022
Director ejecutivoDr. Vlad Coric, M.D.
Número de empleados256
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 23
Dirección215 Church Street
CiudadNEW HAVEN
Bolsa de valoresNYSE Consolidated
PaísUnited States of America
Código postal06510
Teléfono12034040410
Sitio Webhttps://www.biohaven.com/
Símbolo de cotizaciónBHVN
Fecha de salida a bolsaSep 23, 2022
Fundada en2022
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Mr. Kishen (Kishan) Mehta
Mr. Kishen (Kishan) Mehta
Director
Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 14 de may
Actualizado: mié., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
8.23%
1919 Investment Counsel, LLC
6.46%
Childs John W
6.38%
Janus Henderson Investors
6.30%
BlackRock Institutional Trust Company, N.A.
6.19%
Other
66.44%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
37.06%
Investment Advisor
28.02%
Hedge Fund
18.28%
Individual Investor
11.53%
Private Equity
2.88%
Research Firm
2.07%
Sovereign Wealth Fund
0.88%
Bank and Trust
0.64%
Venture Capital
0.51%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
560
104.96M
102.79%
-7.46M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
2023Q1
331
78.42M
114.97%
+3.79M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
8.40M
8.23%
+4.76K
+0.06%
Mar 31, 2025
1919 Investment Counsel, LLC
6.59M
6.46%
+34.44K
+0.53%
Mar 31, 2025
Childs John W
6.51M
6.38%
+351.58K
+5.71%
Mar 10, 2025
Janus Henderson Investors
6.44M
6.3%
-544.20K
-7.79%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.32M
6.19%
-61.68K
-0.97%
Mar 31, 2025
Suvretta Capital Management, LLC
5.62M
5.5%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
4.81M
4.71%
+385.00K
+8.69%
Mar 31, 2025
State Street Global Advisors (US)
3.42M
3.35%
-90.13K
-2.57%
Mar 31, 2025
Coric (Vladimir)
3.18M
3.11%
+26.57K
+0.84%
Mar 10, 2025
RP Management, LLC
2.94M
2.88%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
2.32%
Roundhill GLP-1 & Weight Loss ETF
1.24%
Simplify Health Care ETF
1.16%
Global X Guru Index ETF
1.15%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Tema Neuroscience and Mental Health ETF
0.56%
SPDR S&P Biotech ETF
0.45%
WisdomTree BioRevolution Fund
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Main Thematic Innovation ETF
0.23%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción2.32%
Roundhill GLP-1 & Weight Loss ETF
Proporción1.24%
Simplify Health Care ETF
Proporción1.16%
Global X Guru Index ETF
Proporción1.15%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.85%
Tema Neuroscience and Mental Health ETF
Proporción0.56%
SPDR S&P Biotech ETF
Proporción0.45%
WisdomTree BioRevolution Fund
Proporción0.3%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.26%
Main Thematic Innovation ETF
Proporción0.23%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
